Clinical Trial

NCCH2006/MK010 Trial (FORTUNE Trial)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-arm, open-label, multicenter, investigator-initiated Phase 2 trial to evaluate the efficacy and safety of E7090 in patients with advanced or recurrent solid tumors harboring FGFR genetic alterations (including fusion, mutation, amplification).
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2021-07-12; most recent amendment 2025-09-29.
Status change: Active, Not Recruiting → Recruiting 2025-07-01
Status change: Recruiting → Active, Not Recruiting 2024-01-04
Trial Details
NCT Number NCT04962867
Lead Sponsor National Cancer Center, Japan
Collaborators: Eisai Co., Ltd.
Conditions Advanced or Recurrent Solid Tumors, FGFR Gene Alterations
Enrollment 75 participants
Start Date 2021-06-15
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-03